Health Economics›Pancreatic cancer›Induction therapy for locally advanced disease unresectable

Induction therapy for locally advanced disease unresectable

Pancreatic cancer · 8 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Erlotinib and Gemcitabine Variant #01	—	R 28 195	28d	—	6.1 mo	6	R 94 997 PFS proxy	2
Gemcitabine and RT Variant #01	—	R 5 016	28d	—	15.7 mo	1	R 5 016 PFS proxy	2
GemOx Variant #01	—	R 2 937	14d	5.8 mo	9.0 mo	7	R 20 560 PFS proxy	2
FLEC Variant #01	—	R 2 921	21d	—	7.9 mo	3	R 8 764 PFS proxy	—
Gemcitabine monotherapy Variant #01	—	R 1 672	21d	5.7 mo	6.6 mo	7	R 11 705 PFS proxy	21
Capecitabine monotherapy Variant #01	—	R 1 039	21d	—	—	~35	~R 36 351 PFS proxy · indirect	2
Fluorouracil and RT Variant #01	—	R 809	42d	—	10.0 mo	1	R 809 PFS proxy	1
Radiation therapy N/A - radiation	—	—	49d	—	~9.2 mo	—	—	1

8 of 8 regimens shown